Quality of life associated with treatment of castration-resistant prostate cancer: A review of the literature

Cancer Investigation

Volumn 30, Issue 1, 2012, Pages 1-12

  Moul, Judd W ^a   Dawson, Nancy ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

Burden of illness; Castration resistant prostate cancer; Quality of life; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; ATRASENTAN; CLODRONIC ACID; DOCETAXEL; EPIRUBICIN; ESTRAMUSTINE; FLUTAMIDE; HYDROCORTISONE; MEGESTROL ACETATE; MITOXANTRONE; NAVELBINE; PACLITAXEL; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; SURAMIN; TAX 327; UNCLASSIFIED DRUG; ZIBOTENTAN; ZOLEDRONIC ACID;

ANEMIA; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DECREASED APPETITE; DRUG EFFICACY; FATIGUE; HUMAN; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; ESTRAMUSTINE; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; SURVIVAL; TAXOIDS;

EID: 84855854169     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2011.629381     Document Type: Review

References (55)

1. Jemal A, Siegel R, Xu J,Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300
2. World Health Organization. Prostate cancer incidence and mortalityworldwide in 2008 (summary).Available at: . iarc.fr/factsheets/cancers/ prostate.asp (accessed Oct. 1, 2010).
3. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765-781.
4. Jemal A, Bray F, Center MM, Ferlay J,Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
5. Kvale R, Auvinen A, Adami HO, Klint A, Hernes E, Moller B, Pukkala E, Storm HH, Tryggvadottir L, Tretli S, Wahlqvist R, Weiderpass E, Bray F. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst 2007;99:1881-1887. (Pubitemid 351767195)
6. Jemal A, Siegel R,WardE, HaoY,Xu J,ThunMJ.Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
7. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010;28:1117-1123.
8. Gelmann EP. Androgen receptor biology in prostate cancer. In Drug Management of Prostate Cancer, WD Figg, CH Chau, and EJ Small (eds.). New York: Springer, 2010, 61-70.
9. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-422.
10. Penson DF, Litwin MS. The physical burden of prostate cancer. Urol Clin North Am 2003;30:305-313. (Pubitemid 36520602)
11. Petrylak DP, Tangen CM, HussainMH, Lara PN, Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine comparedwithmitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-1520. (Pubitemid 39315318)
12. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA.Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512. (Pubitemid 39315317)
13. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147-1154.
14. Antonarakis ES, Carducci MA, Eisenberger MA. Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett 2009;291:1-13.
15. de Bono JS, Logothetis CJ, Fizazi K, North S, Chu L, Chi KN, KheohT, HaqqC, Molina A, ScherHI, on behalf of theCOU-AA- 301. Abiraterone acetate plus low dose prednisone improves overall survival in patients withmetastatic castration resistant prostate cancer who have progressed after docetaxel-based chemotherapy: results of COU-AA-301, a randomized double-blind placebocontrolled phase III study. Ann Oncol 2010;21:viii3.
16. Fossa SD,Aaronson NK,Newling D, vanCangh PJ,Denis L,Kurth KH, de PauwM.Quality of life and treatment of hormone resistant metastatic prostatic cancer: the EORTC Genito-Urinary Group. Eur J Cancer 1990;26:1133-1136.
17. Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Stewart L, Rider W. Treatment of metastatic prostatic cancer with lowdoseprednisone: evaluationof painandqualityof life as pragmatic indices of response. J Clin Oncol 1989;7:590-597. (Pubitemid 19126794)
18. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CML, Murphy KC. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-1764. (Pubitemid 26185452)
19. Galceran CJ, Bastus Piulats R, Martin-Broto J, Maroto Rey P, Nogue Aligue M, Domenech Santasusana M, Arcusa Lanza A, BellmuntMolins J, Colin C, Girard A. A phase II study of vinorelbine and estramustine in patients with hormone-resistant prostate cancer. Clin Transl Oncol 2005;7:66-73.
20. Fossa SD. A randomized phase II trial comparing weekly taxotere plus prednisolone versus prednisolone alone in androgenindependent prostate cancer. Front Radiat Ther Oncol 2008;41: 108-116.
21. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, Schulman CC, Nabulsi AA, Humerickhouse RA, WeinbergMA, Schmitt JL, Nelson JB. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003;21:679-689. (Pubitemid 46621903)
22. Berry WR, Hathorn JW, Dakhil SR, Loesch DM, Jackson DV, Gregurich MA, Newcomb-Fernandez JK, Asmar L. Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancer. Clin Prostate Cancer 2004;3:104-111. (Pubitemid 39403229)
23. Dawson N, Payne H, Battersby C, Taboada M, James N. Healthrelated quality of life in pain-free or mildly symptomatic patients with metastatic hormone-resistant prostate cancer following treatment with the specific endothelin A receptor antagonist zibotentan (ZD4054). J Cancer Res Clin Oncol 2010;137:99-113.
24. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, Investigators TAX. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512. (Pubitemid 39315317)
25. Fossa SD, Slee PHT, Brausi M, Horenblas S, Hall RR, Hetherington JW, Aaronson N, de Prijck L, Collette L. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European Organization for Research and Treatment of Cancer genitourinary group. J Clin Oncol 2001;19:62-71. (Pubitemid 32063480)
26. Small EJ, Meyer M, Marshall ME, Reyno LM, Meyers FJ, Natale RB, Lenehan PF, Chen L, Slichenmyer WJ, Eisenberger M. Suramin therapy for patients with symptomatic hormonerefractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol 2000;18:1440-1450. (Pubitemid 30205389)
27. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-1468.
28. BerryDL,MoinpourCM, JiangCS, AnkerstDP, PetrylakDP,Vinson LV, Lara PN, Jones S, Taplin ME, Burch PA, Hussain MHA, Crawford ED. Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine tomitoxantrone and prednisone. J Clin Oncol 2006;24:2828-2835. (Pubitemid 46630582)
29. Petrioli R, Fiaschi AI, Pozzessere D, Messinese S, Sabatino M, Marsili S, Correale P, Manganelli A, Salvestrini F, Francini G. Weekly epirubicin in patients with hormone-resistant prostate cancer. Br J Cancer 2002;87:720-725. (Pubitemid 35178748)
30. Ahles TA, Herndon JE, II, Small EJ, Vogelzang NJ, Kornblith AB, Ratain MJ, Stadler W, Palchak D, Marshall ME, Wilding G, Petrylak D, Holland JC. Quality of life impact of three different doses of suramin in patients with metastatic hormonerefractory prostate carcinoma: results of Intergroup 0159/ Cancer and Leukemia Group B 9480. Cancer 2004;101:2202-2208. (Pubitemid 39458674)
31. Ernst DS, Tannock IF, Winquist EW, Venner PM, Reyno L, Moore MJ, Chi K, Ding K, Elliott C, Parulekar W. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 2003;21:3335-3342. (Pubitemid 46613484)
32. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D,Winer EP, Vogelzang NJ. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clinl Oncol 1999;17:2506-2513. (Pubitemid 29368252)
33. Dawson NA, Conaway M, Halabi S, Winer EP, Small EJ, Lake D, Vogelzang NJ. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: Cancer and Leukemia Group B Study 9181. Cancer 2000;88:825-834. (Pubitemid 30091102)
34. AaronsonNK, Ahmedzai S, BergmanB,BullingerM, Cull A,Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JCJM, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376. (Pubitemid 23073154)
35. Johansson JE,Wersall P, Brandberg Y, Andersson SO, Nordstrom L, Study Group EPO. Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer: a randomized study. Scand J Urol Nephrol 2001;35:288-294. (Pubitemid 32906850)
36. Borghede G, Sullivan M. Measurement of quality of life in localized prostatic cancer patients treated with radiotherapy: development of a prostate cancer-specific module supplementing the EORTC QLQ-C30. Qual Life Res 1996;5:212-222. (Pubitemid 26180669)
37. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB,Winicour P, Brannon J, Eckberg K, Lloyd S, Purl S, Blendowski C,GoodmanM, BarnicleM, Stewart I,McHale M, Bonomi P, Kaplan E, Taylor S, IV,Thomas, CR, Jr,Harris J.The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993;11:570-579. (Pubitemid 23071057)
38. Esper P, Mo, F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 1997;50:920-928. (Pubitemid 28021111)
39. Osoba D, Tannock IF, Ernst DS, Neville AJ. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 1999;17:1654-1663. (Pubitemid 29269233)
40. Schipper H, Clinch J,McMurray A, Levitt M.Measuring the quality of life of cancer patients: the Functional Living Index-Cancer - development and validation. J Clin Oncol 1984;2:472-483. (Pubitemid 14075981)
41. Johnson C, Fitzsimmons D, Gilbert J, Arrarras J-I, Hammerlid E, Bredart A, Ozmen M, Dilektasli E, Coolbrandt A, Kenis C, YoungT, ChowE, VenkitaramanR, Howse F,George S,O'Connor S, Yadegarfar G, EORTC Quality of Life Group. Development of the European Organisation for Research and Treatment of Cancer quality of life questionnaire module for older people with cancer: the EORTC QLQ-ELD15. Eur J Cancer 2010;46:2242-2252.
42. Cella D, Nichol MB, Eton D, Nelson JB, Mulani P. Estimating clinically meaningful changes for the functional assessment of cancer therapy - prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. ValueHealth 2009;12:124-129.
43. King MT.The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 1996;5:555-567. (Pubitemid 27006967)
44. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16:139-144. (Pubitemid 28041591)
45. Scher HI, Halabi S, Tannock I,MorrisM, Sternberg CN, Carducci MA, EisenbergerMA,HiganoC, BubleyGJ,DreicerR, PetrylakD, Kantoff P, Basch E, Kelly WK, FiggWD, Small EJ, Beer TM,Wilding G,Martin A, Hussain M. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical TrialsWorking Group. J Clin Oncol 2008;26:1148-1159.
46. Berthold DR, Pond GR, Roessner M, de Wit R, Eisenberger M, Tannock AI, investigators TAX. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 2008;14:2763-2767.
47. Dowling AJ, Panzarella T, Ernst DS, Neville AJ, Moore MJ, Tannock IF. A retrospective analysis of the relationship between changes in serum PSA, palliative response and survival following systemic treatment in a Canadian randomized trial for symptomatic hormone-refractory prostate cancer. Ann Oncol 2001;12:773-778. (Pubitemid 32655085)
48. Collette L, Burzykowski T, Schroder FH. Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of longterm therapeutic benefit in prostate cancer trials. Eur J Cancer 2006;42:1344-1350. (Pubitemid 43922404)
49. Newling DWW. Issues with the use of prostate-specific antigen as a surrogate end point in hormone-resistant prostate cancer. Eur Urol Suppls 2009;8:13-19.
50. Mulders PF, Schalken JA. Measuring therapeutic efficacy in the changing paradigm of castrate-resistant prostate cancer. Prostate Cancer Prostatic Dis 2009;12:241-246.
51. Granda-Cameron C, Viola SR, LynchMP, Polomano RC.Measuring patient-oriented outcomes in palliative care: functionality and quality of life. Clin J Oncol Nurs 2008;12:65-77.
52. Sloan JA, Berk L, Roscoe J, Fisch MJ, Shaw EG,Wyatt G, Morrow GR,DueckAC. Integrating patient-reported outcomes into cancer symptom management clinical trials supported by the National Cancer Institute-sponsored clinical trials networks. J Clin Oncol 2007;25:5070-5077. (Pubitemid 350232285)
53. Lipscomb J, Reeve BB, Clauser SB, Abrams JS, Bruner DW, Burke LB, Denicoff AM, Ganz PA, Gondek K, Minasian LM, O'Mara AM, Revicki DA, Rock EP, Rowland JH, Sgambati M, Trimble EL. Patient-reported outcomes assessment in cancer trials: taking stock, moving forward. J Clin Oncol 2007;25:5133-5140. (Pubitemid 350232295)
54. Levine MN, Ganz PA. Beyond the development of quality-oflife instruments: where do we go from here? J Clin Oncol 2002;20:2215-2216. (Pubitemid 34441645)
55. Colloca G, Colloca P. Health-related quality of life assessment in prospective trials of systemic cytotoxic chemotherapy for metastatic castration-resistant prostate cancer: which instrument we need? Med Oncol 2010;28:519-527.